AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 30 - (NewsRx.com & NewsRx.net) -- CancerVax Corp. has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a pivotal (Phase II/III) clinical trial of the Canvaxin therapeutic cancer vaccine as a treatment for metastatic colon cancer.
"We are very pleased with the achievement of this important milestone for CancerVax," said David F. Hale, president and chief executive officer. "There is a significant need for more effective and safer therapeutics for the treatment of advanced metastatic colon cancer, which is one of the deadliest forms of cancer in the U.S. and the world. With the start of this pivotal trial, following FDA review of the protocol, Canvaxin will be in late-stage, multicenter clinical trials for two cancers for which there are currently no adequate therapies - advanced metastatic colon cancer and metastatic melanoma."
The Canvaxin vaccine, CancerVax's lead product candidate, is an allogeneic whole-cell vaccine that expresses at least 20 known tumor-associated antigens, 14 of which are specifically cross-reactive with colon cancer, which the company believes enhances overall immune response to the cancer. Unlike ...